Bone Health

Romosozumab Biosimilar Matches Reference in Functional Testing Despite Disulfide Differences

July 16th 2026

By Brooke McCormick

A romosozumab biosimilar showed comparable sclerostin binding and bone-signaling potency to the reference product despite disulfide isoform differences.

Biosimilar Denosumab Matches Reference Drug for Bone Density in Chinese Women

July 6th 2026

By Skylar Jeremias

Phase 3 data show denosumab biosimilar KN012 matches Prolia for BMD gains and safety, potentially expanding affordable osteoporosis care.

Biosimilar Switching Maintained Disease Control in People With Ankylosing Spondylitis

June 16th 2026

By Skylar Jeremias

Evidence shows biosimilars switching in ankylosing spondylitis maintains disease control with biologics, cuts costs, and highlights nocebo risks.

FDA Approves Teva Biosimilar for Denosumab in Osteoporosis

March 31st 2026

By Sabrina McCrear

The FDA approved Teva’s biosimilar for denosumab, and the FDA and EMA accepted its asthma biosimilar application for review.

Trial Data Support Equivalence of Denosumab Biosimilar in Postmenopausal Osteoporosis

January 16th 2026

By Skylar Jeremias

Denosumab biosimilars enhance treatment access for postmenopausal osteoporosis, demonstrating equivalent efficacy and safety to reference products in recent trials.

Eye on Pharma: Global Approvals, Launches, and Strategic Partnerships

January 12th 2026

By Skylar Jeremias

FDA Approves Amneal Denosumab Biosimilars, Capping Year of Market Expansion

January 6th 2026

By Skylar Jeremias

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving competition and cost savings.

Top 5 Most-Read Bone Health Articles of 2025

December 24th 2025

By Skylar Jeremias

Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in 2025.

Denosumab, Golimumab Biosimilars Clear Major Regulatory Milestones in Europe, as US Hurdles Remain

December 16th 2025

By Skylar Jeremias

Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US market entry delays.

Economic Analysis Supports Formulary Shift to Biosimilar Denosumab

November 26th 2025

By Skylar Jeremias

Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in oncology care while enhancing patient outcomes.